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ABSTRACT
We investigated DNA methylomes of pediatric B-
cell acute lymphoblastic leukemias (B-ALLs) us-
ing whole-genome bisulfite sequencing and high-
definition microarrays, along with RNA expression
profiles. Epigenetic alteration of B-ALLs occurred in
two tracks: de novo methylation of small functional
compartments and demethylation of large inter-
compartmental backbones. The deviations were ex-
aggerated in lamina-associated domains, with differ-
ences corresponding to methylation clusters and/or
cytogenetic groups. Our data also suggested a piv-
otal role of polycomb and CTBP2 in de novo methy-
lation, which may be traced back to bivalency status
of embryonic stem cells. Driven by these potent epi-
genetic modulations, suppression of polycomb tar-
get genes was observed along with disruption of de-
velopmental fate and cell cycle and mismatch repair
pathways and altered activities of key upstream reg-
ulators.
INTRODUCTION
Our understanding of the cancer epigenome has expanded
from the canonical view of promoter DNA methylation
and gene silencing to incorporate an intricate landscape
(1). De novo methylation in promoter CpG islands (CGIs)
and global demethylation in intergenic repeat sequences
and gene bodies are now recognized as hallmarks of can-
cer (2). Connections between DNA methylation and his-
tone, polycomb and transcription factor (TF) proteins are
increasingly apparent (1,3). The characterization of an ab-
normal departure from normal developmental states is typ-
ically challenged by the difficulty in obtaining appropri-
ate control sets of early relevant stages. Here, we investi-
gated genome-wide DNA methylomes of B-cell acute lym-
phoblastic leukemias (B-ALLs), the most common cancer
in children, in reference to their normal B-cell precursors
(pre-B).
MATERIALS AND METHODS
B-ALL samples and nucleic acids extraction
A total of 231 pediatric patients with B-ALL were utilized
from the California Childhood Cancer Study. After exclu-
sion by quality check described below, 227 patients were fi-
nally analyzed, including 206 patients with unequivocal cy-
togenetic classification. After informed consent, bone mar-
row specimens packed with leukemic blasts were obtained
for each patient. Mononuclear cells were purified using Fi-
coll. Genomic DNA and total RNAwere isolated using the
AllPrep DNA/RNAMini Kit (Qiagen).
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Control pre-B cells and other blood cells
Expression and methylation data of purified pre-B cells in
four developmental stages were retrieved from our previ-
ous study (4), and by the established protocol, pre-B-II cells
for whole genome bisulfite sequencing (WGBS) were pu-
rified. Purified normal mature B-cells, T-cells, regulatory
T-cells, NK-cells, monocytes and granulocytes were pur-
chased from the Allcells Corp. DNAs were extracted as de-
scribed above.
WGBS and library construction
WGBS was conducted as described previously (5). Briefly,
unmethylated  DNA (Promega) was spiked into genomic
DNA. We sheared the DNA by sonication to 50–500 bp
with a Covaris E220, followed by selecting 150- to 300-
bp fragments using AMPure XP beads (Agencourt Bio-
science). Genomic DNA libraries were constructed using
the TruSeq Sample Preparation kit (Illumina). After adap-
tor ligation, two rounds of sodium bisulfite-conversion of
DNA using the EpiTexy Bisulfite Kit (Qiagen) were per-
formed to get a conversion efficiency of>99%.We enriched
adaptor-ligated DNA through seven cycles of PCR using
the PfuTurboCx Hotstart DNA polymerase (Stratagene).
Library quality was monitored using the Agilent 2100 Bio-
Analyzer (Agilent) and KAPA Library Quantification Kit
(Kapa Biosystem). Paired-end sequencing (2× 100 bp) was
then carried out using the Illumina Hi-Seq 2000.
Read mapping and methylation% estimation
From the human genome (GRCh37) and NCBI viral
genome (v35), two reference sequences including reference
C2T (all Cs were replaced by T) and reference G2A (all
Gs were replaced by A) were generated, and to these, each
paired-end read was aligned using the GEM software (6).
Up to four mismatches were allowed, and read pairs with
unique compatible mappings (to the same chromosome and
in the expected orientation) were selected. After mapping,
most likely genotype and methylation% in each C were esti-
mated, using the software developed at the CentroNacional
de Ana´lisis Geno´mico, which takes into account the ob-
served bases, base quality scores and the strand origin of
each read pair. The confidence in the genotype call was es-
timated by the Phred-scaled likelihood. CpG sites were se-
lected where both bases were called as homozygous CC fol-
lowed by GG with a Phred score of ≥20. Sites with >500×
coverage depth were excluded to avoid highly repetitive re-
gions (5).
High-definition methylation array
Genomic DNA was bisulfite-converted using the EZ DNA
Methylation Kit (Zymo Research), followed by hybridiza-
tion onto the Infinium HumanMethylation450 Beadchip
(Illumina). Raw data was normalized and further processed
using the GenomeStudio software (Illumina) and R soft-
ware packages including methylumi and others. CpG sites
with poor quality (detection P > 1.0 × 10−4) were re-
moved from analysis, and four samples with high propor-
tion (>15%) of poor CpG sites were excluded. Additional
450k array data of relapsed B-ALLs was obtained from a
clinical set of patients (GSE49031) (7).
Genomic annotation and definition of regions
Data was annotated from the UCSC Genome Browser
database (version hg19), using RefSeq Genes, lincRNA
Transcripts, CpG Islands, Vista Enhancers, ENCODE
Transcription Factor ChIP-Seq, DNase Clusters, LaminB1
(LAD), and RepeatMasker tracks. ChIP-Seq data of H1
ESC was retrieved from the UCSF-UBC Human Refer-
ence EpigenomeMapping Project (GSE16368). For histone
mark information in somatic tissues, we retrieved the Broad
Histone track from the USCS browser. For genes with mul-
tiple isoforms, the longest one was used as the reference. A
‘promoter’ was designated to be from −1.5 kb upstream to
the transcriptional start site of each gene. We defined ‘CGI
shores’ as 0–2 kb from the CGI edge and CGI shelf as 2–
4 kb. By scaling from the whole gene body length, we de-
fined ‘5′-body’ as 0–0.1 fractional region and ‘main body’ as
0.1–1.0. After removing all promoters, 5′-body, exon, exon–
intron boundary (±100 bp), CGI, CGI shore, DNase HS,
TF-binding and enhancer sites, we designated the remain-
ing region as ‘backbone.’
DMR statistics
For both WGBS and array data, ‘DMR’ was defined as
a CpG with >20% difference of methylation. When com-
paring two groups, array methylation β values were con-
verted by the equation of ‘arcsine[square root(β)]’ to per-
form parametric statistical analysis. Moderated T-statistics
and false discovery rate (FDR)-correction were performed,
and from this, P < 0.01 was used as an additional criteria
for defining DMRs. The occurrence of DMRs in specified
regions was examined by χ2 or Fisher-exact tests.
TF and motif enrichment
Using WGBS data, we constructed DMR-blocks by select-
ing CpGs with >25% mean difference between case and
control and merging consecutively changed CpGs within
500 bp of distance into a single DMR-block. Then we ex-
amined positional enrichment of DMR-blocks around 148
ENCODE TF binding sites using Homer software (8). For
array data, the enrichment was assessed by calculating the
enrichment rate of single DMRs and by Fisher-exact test.
After retrieving sequences around each DMR CpG (±25
bp) along with those around non-DMR CpGs randomly
chosen as a background, motif analysis was carried out us-
ing Homer software with CpG-density normalization.
RNA expression analysis
Total RNA was amplified and labeled (NuGen Ovation)
and hybridized onto the GeneChip Human Gene 1.0 ST
Array (Affymetrix), according to standard protocols. Data
was normalized using the Expression Console software
(Affymetrix) with the Robust Multi-array Average (RMA)
algorithm. Further analysis was done using the R soft-
ware package. DEGs were defined by fold-change>1.5 and
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FDR-corrected P < 0.01. Gene Set Enrichment Analysis
was done using B-cell developmental gene sets retrieved
from our previous work (Up-DEGs from S2 to S3) (4) and
polycomb target gene sets from a study by Lee et al. (9).
Pathway analysis was performed using the Ingenuity Path-
wayAnalysis software (Ingenuity System). Additionally, the
expression array data of mature peripheral B-cells was ob-
tained from another study (GSE46261).
ROC curve analysis
To identify CpGs or genes that best discriminate one group
from another, we performed receiver operating characteris-
tic (ROC) curve analysis for each CpG or gene. After filter-
ing by average differences, CpGs or genes were ranked ac-
cording to area under the curve (AUC) values of the ROC
analysis.
Data access
Rawdata for the current study is available in theNCBIGene
Expression Omnibus (GEO) (GSE56602).
RESULTS
Whole DNA methylomes at single base-pair resolution
We first bisulfite sequenced, at single-base pair resolu-
tion, two common pediatric B-ALL cancers including
ETV6/RUNX1 rearrangement (ETV6-ALL) from a 3-year-
old girl and high hyperdiploid (HD-ALL) from a 1-year-
old boy (representing clusters III and I described below, re-
spectively; Supplementary Table S1), in parallel with nor-
mal pre-B-II cells obtained from the same source as those
used in our previous study (4) and processed as a part of
the Blueprint Consortium. Bisulfite-converted DNA was
sequencedwith average coverage of 46.6 and 49.6 for ETV6-
ALL and HD-ALL, respectively, yielding >700 million
high-quality reads and >80% unique alignment (Supple-
mentary Table S2). About 20 million CpGs among all 28
million human genomic CpGs were uniquely mapped with
high quality and further analyzed (Supplementary Table
S3). WGBS data was validated with high correlation (r >
0.97) to Illumina 450k array data (Supplementary Figure
S1A). Unlike embryonic stem cells (ESCs) (10) and like
other somatic cells (11), methylation at non-CpG sites was
unnoticeable in our samples.
The majority of CpGs were hypermethylated, and con-
secutive CpGs with similar methylation levels constituted
methylation blocks. Methylated blocks in HD-ALL were
larger in number but smaller in size, and as a result, cov-
ered less genomic area than themethylated blocks of ETV6-
ALL (Supplementary Figure S1B–D). The net methylation
level of ETV6-ALL was almost equal to that of the pre-B
cell control, while that of HD-ALL was 4.4% lower (Figure
1A; Supplementary Table S3). Compared to pre-B cells, de
novomethylation mostly occurred in originally hypomethy-
lated CpGs while demethylation did so in originally hyper-
methylated CpGs, with demethylation beingmore profound
in HD-ALL (Figure 1B and C). We identified 1 315 701
and 2 065 605 differentially methylated regions (DMRs) in
ETV6-ALL and HD-ALL, respectively; these were highly
concordant with the Illumina 450k array DMRs (Supple-
mentaryTable S4). The vastmajority of genes in the genome
had one or more DMR(s) within their promoter or body re-
gions (Figure 1D). Demethylated DMRs (de-DMRs) out-
numbered de novomethylatedDMRs (de novoDMRs) espe-
cially in HD-ALL (1 741 261 versus 324 344 in HD-ALL;
826 237 versus 489 464 in ETV6-ALL). There were a num-
ber of DMRs that overlap between ETV6-ALL and HD-
ALL (89.5% among the twoWGBS samples) but also a sub-
stantial number of sample-specific DMRs (Supplementary
Tables S3 and S4).
We retrieved potentially regulatory regions including
CGIs, DNase hypersensitive sites (HS), and transcription
factor (TF) binding sites, by combining all regions from
various cell types from the ENCODE project, and inves-
tigated methylation changes in each type. In both can-
cers, CpGs in promoter, 5′-body (0–0.1 in fractional re-
gion of gene body) and CGI are more enriched for de novo
DMRs while those in ‘CGI shelf ’ and repeat regions were
enriched for de-DMRs. TF binding sites and DNase HS
are more enriched for de novo methylation in ETV6-ALL
and for demethylation in HD-ALL (Figure 1E; Supplemen-
tary Table S5). This distribution can be interpreted in re-
gard to methylation levels in normal cells; CGIs and pro-
moters are mostly hypomethylated in pre-B cells, and ac-
cordingly, de novo DMRs at these sites occur in large part
at CpGs with low methylation. Main body and repeat re-
gions are mostly methylated in normal cells so de-DMRs
are often at such methylated sites (Supplementary Table
S6). On average, CGIs were methylated to similar degrees
(∼+10%), regardless of genic locations. However, due to the
dense localization of CGIs in promoters and 5′-bodies, de
novo DMRs were far more enriched in such regions (Sup-
plementary Figure S2). DNase HS in promoters and 5′-
bodies were profoundly methylated but such a trend was
only modest or negligible in main body and intergenic re-
gions (Figure 2A). Exons in main gene bodies were less al-
tered while introns, especially the deep portion of long in-
trons, were profoundly demethylated in HD-ALL but not
in ETV6-ALL (Figure 2B). By excluding all small func-
tional compartments including promoters, 5′-bodies, exons,
CGIs, CGI shores, DNase HS, TF-binding sites and en-
hancer sites, we retrieved the remaining large frame-like re-
gions and defined them as ‘backbones’. The regions largely
overlap with those often referred to as ‘open sea’, and cover
the vast majority of CpGs, especially those in introns and
intergenic regions in the human genome, and are mostly hy-
permethylated. Backbones of ETV6-ALL were maintained
in a hypermethylated state but those ofHD-ALLwere glob-
ally demethylated (∼−5%) (Figure 2C andD). Unlike other
cultured cell-lines and normal placental tissues but compa-
rable to most other cells from somatic tissues (12,13), par-
tially methylated domains (PMDs) were absent both in our
B-ALLs and normal pre-B cells. However from a whole
genome view, we observed a trend that some large regions
are slightly demethylated in HD-ALL. The subtle change
overlapped with the lamina associated domains (LADs), as
defined by (14), as well as PMDs in other cancers which
share many regions with LADs (11) (Supplementary Fig-
ure S3). Although the definition of LADs were retrieved
from normal fibroblasts, the majority of LADs were shown
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Figure 1. Overview and statistics of whole-genome bisulfite sequencing data of B-ALLs and normal pre-B cells. (A) Circular barplots of genome-wide
average methylation levels in pre-B cells, ETV6-ALL and HD-ALL (from inside to outside, bin size = 5 Mb) showing slight demethylation of HD-ALL
throughout genomic location. (B and C) Density plots of DNAmethylation levels of all autosomal CpGs between B-ALL and pre-B cells. Individual CpG
site methylation of pre-B cell and B-ALL are expressed on the X- and Y-axes. Hotter colors indicate higher density of data. (D) Counts of differentially
methylated regions (DMRs; CpGs with methylation difference >20%) within genes or promoters. Most genes have more than one DMR inside the genic
region or promoters, with some genes having numerous DMRs. HD-ALL had more de-DMRs than ETV6-ALL. (E) Relative distribution of DMRs
according to specified regions. In both tumors, CpGs in promotes, 5′-body (0–0.1 in fractional region of gene body) and CpG island (CGI) are more
enriched for de novo DMRs while CGI shelf and repeat regions were so for de-DMRs. Transcription factor (TF) binding sites and DNase hypersensitive
sites (HS) are more enriched for de novo methylation in ETV6-ALL and for demethylation in HD-ALL.
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Figure 2. DNAmethylation changes of B-ALLs compared to pre-B cell according to specified regions. (A) Local regression showing methylation difference
in DNase HS, stratified by genic location. DNase HS in promoter and 5′-body are more likely to be methylated, while the trend was slight or negligible in
main body and downstream regions. (B) Methylation difference in exons and introns in gene main bodies. Exons are less altered while introns, especially
the deep portion of long introns, are profoundly demethylated in HD-ALL but not in ETV6-ALL. (C) Genome-wide overview of methylation changes
in backbones defined by regions devoid of promoters, 5′-bodies, exons, CGIs, CGI shores, DNase HS, TF-binding sites and enhancer sites. ETV6-ALL
demonstrates minimal change when compared with the pre-B cell control. (D) Genome-wide view of methylation changes in backbones of HD-ALL show
profound demethylation across the whole genome. Red bars indicate chromosomes with extra copies. (E) Methylation changes of backbones according
to location to lamina-associated domain (LAD) show more demethylation of regions inside LADs in HD-ALL. (F) Methylation differences in CGI and
DNase HS, stratified by location to LAD show profound de novo methylation of CGI and DNase HS inside LAD.
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to be constitutively conserved in various tissues (15) and
so we used this defined region in further analysis as a sur-
rogate for the large repressive epigenetic domains. Back-
bone demethylation was exaggerated in LADs, especially
in HD-ALL, which contrasts to the trend that small func-
tional sites includingCGIs andDNAseHS aremore de novo
methylated in LADs (Figure 2E and F). Most repeat fami-
lies were demethylated but centromere, acrocentric, satellite,
tRNA, rRNA, simple repeat and low complexity families
were preferentially de novo methylated (Supplementary Ta-
ble S7).
Gene expression correlated negatively with DNA methy-
lation in promoters and 5′-bodies, and even in those re-
gions, the trend was particularly remarkable in CGIs or
DNase HS (Figure 3A and B; Supplementary Figure S4A
and B). Demethylation of main bodies of low-level ex-
pressed genes was noted in HD-ALL but not in ETV6-ALL
(Figure 3A; Supplementary Figure S4A). Plotting methy-
lation values of CpGs in RB1, an exemplary tumor sup-
pressor gene down-regulated in B-ALLs, illustrated typi-
cal patterns: ETV6-ALL preferentially had promoter CGIs
methylated while HD-ALL rather had gene body, including
deep introns, demethylated (Supplementary Figure S4C).
Highly expressed genes had a tendency to maintain hy-
pomethylated promoters and hypermethylated gene bodies,
in concordance with the theory that gene body hypermethy-
lation helps to dampen transcriptional noise and maintain
high expression of intact mRNA (16,17). However, the situ-
ation may vary in different genes and it appears that expres-
sion is confounded by many factors (Supplementary Figure
S4D–G).
Enrichment of specific TFs related to ESC bivalency
After reconstituting de novo and de-DMR blocks, we
screened them against the binding sites of 148 TFs from
ENCODE. Two TFs, SUZ12 and CTBP2, were remark-
ably enriched around de novo DMRs, and most TFs were
poorly enriched around de-DMRs (Figure 4A and B; Sup-
plementary Figure S5A and B). We further investigated
DNA methylation changes in association with histone sig-
natures by obtaining ChIP-Seq data of H1 human embry-
onic stem cell and found that bivalent domains of ESCs,
marked by H3K4me3 and H3K27me3 co-occupancy (18),
are more likely to be de novo methylated in B-ALLs (Fig-
ure 4C; Supplementary Figure S5C). We performed simi-
lar analysis using histone marks from different types of so-
matic tissues. Compared to ESCs, bivalent regions in the
somatic cells were much smaller but still showed higher
enrichment rates for de novo DMRs. Rather, those cells
had large H3K27me3 domains, which should have replaced
the bivalent domains during differentiation (19), and as
to absolute numbers, de novo DMRs were far enriched in
the H3K27me3 single-occupancy domain (Supplementary
Figure S6). Positional comparisons between histone signa-
tures and TF-binding sites suggested that CTBP2 is actu-
ally linked to the H3K4me3 portion and SUZ12 is to the
H3K27me3 portion of the bivalent domain in ESC (Fig-
ure 4D). An exemplary gene is illustrated in Figure 4E; the
promoter of ALX4 is occupied with both H3K4me3 and
H3K27me3 histone marks in human ESC, and when dif-
ferentiated, the gene is activated in normal skeletal muscle
(HSMM cell-line) by H3K4me3 single-occupancy (i.e. by
loss of H3K27me3) while suppressed in normal lung fibrob-
lasts (NHLF cell-line) by H3K27me3 single-occupancy (i.e.
by loss of H3K4me3). In both ALLs, de novo DMRs are
highly enriched in such bivalent regions at the promoter,
which also overlap with CGIs as well as SUZ12- and
CTBP2-binding sites. It is noteworthy that the H3K4me3
peaks of the bivalent domain frequently coincide with the
CTBP2-binding sites (Figure 4E).
Motifs of REST/NRSF, PU.1, HOX and GATA fami-
lies were significantly enriched in de novoDMRs, especially
in ETV6-ALL, whereas motifs of onco-proteins including
ERG and MYC and B-cell developmental TFs including
EBF were more enriched in de-DMRs, especially in HD-
ALL. We also discovered novel motifs enriched in DMRs
(Figure 4F; Supplementary Table S8).
Genome-wide methylation profiles of B-ALLs
We next analyzed methylation profiles of 227 pediatric B-
ALLs using Illumina 450k array (Supplementary Table S9).
From our previous work (4), we also included data of pu-
rified pre-B cells representing four ordered developmental
stages including multipotent progenitor, pre-B-I, pre-B-II
and immature B cells. Using 5021 differentiation-associated
DMRs, we calculated similarity scores to find that most B-
ALLs are concordant to the last three stages but not the
first stage (Supplementary Figure S7A). Accordingly, the
last three stage cells were used as controls. Among the 472
499 autosomal CpGs that passed quality control, 26 874
(5.7%) around 4671 genes were de novo DMRs and 23 909
(5.1%) around 9854 genes were de-DMRs (Supplementary
Figure S7B). De novo DMRs were overrepresented in the
promoter and 5′-body, and de-DMRs were overrepresented
in the main body (Supplementary Figure S7C and S8).
An unsupervised hierarchical clustering using the 500
most variable CpGs divided samples into four distinct clus-
ters (Figure 5A). Cluster I mainly contained hyperdiploid
cases, cluster II had ‘others’ cases and a small number of
ETV6/RUNX1 cases, cluster IIImostly hadETV6/RUNX1
cases, and cluster IV had ‘others’ and ETV6/RUNX1 cases.
In each cytogenetic group, methylation clusters represented
different epigenetic status in CGI, with clusters III and
IV having more methylation (Figure 5B). The cytogenetics
groups or methylation clusters largely shared DMRs that
may be common for all B-ALLs but each group/cluster also
had specific DMRs (Figure 5C and Supplementary Figure
S9A). The numbers of DMRs in individual leukemias var-
ied across broad ranges (de novo DMRs from 3070 to 89
511 and de-DMRs from 9677 to 89 033) and were related
to methylation clusters; cluster IV had larger numbers of
DMRs while cluster II had smaller numbers (Supplemen-
tary Figure S9B). We also identified top CpGs discriminat-
ing hyperdiploid and ETV6/RUNX1 (Supplementary Fig-
ure S10).
As a replication of the findings from WGBS, we could
also observe de novo methylation of promoter, 5′-body and
CGIs and demethylation of main body and CGI shelves
but the degrees differed in each leukemia and related to
methylation clusters (Supplementary Figure S8A). We also
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Figure 3. Association between DNA methylation and gene expression. (A) Local regression showing methylation levels of HD-ALL according to genic
locations, stratified by expression quintile. Genes in the highest expression quintile tend to have their promoter unmethylated and gene body mostly
methylated. (B) Methylation levels of HD-ALL in CGI and DNase HS, stratified by genic location and expression quintile. Methylation in CGI and
DNase HS located around promoter and 5′-body apparently correlated with expression while not in the remaining regions.
observed the trend that CGIs are methylated regardless of
genic location and DNase HS are more methylated around
promoters and the 5′-body. However, the trends in DNase
HS were quite differing in each leukemia and each clus-
ter, with some leukemias having negative average differences
(Supplementary Figure S8B). As observed in WGBS cases,
de novo methylation in CGIs and DNase HS are more re-
markable inside LADs (Supplementary Figure S8C).
A total of 8738 CpGs around 182 putative imprinted
genes were selected and found to be less altered during nor-
mal development but more likely to be de novo methylated
in B-ALLs, compared to those around non-imprinted genes
(10.3% versus 5.6%) (Supplementary Table S10).
We retrieved methylation values of the CGI and back-
bone regions from the array data. Four methylation clus-
ters behaved differently in terms of CGI methylation and
backbone demethylation (Supplementary Figure S11A). As
to cytogenetic groupings, hyperdiploid leukemias had back-
bones more demethylated than ETV6/RUNX1 (Supple-
mentary Figures S11B and S12A). These trends were far ex-
aggerated in CpGs in LADs (Supplementary Figure S11C
and D). Analysis on a clinical cohort (7) illustrated that re-
lapsed clones tend to have intensified CGI methylation and
slight backbone demethylation; 20 among the 24 cases in
the cohort had CGI altered methylation by more than 0.05,
and 11 among the 24 cases had backbone demethylation by
more than 0.01 (Supplementary Figure S11E). The average
methylation values of backbones in some LADs correlated
strongly with each other (Supplementary Figure S12B and
C).
We further scanned the ENCODE TF tracks and again
found significant enrichment of SUZ12 and CTBP2 (en-
richment rates 11.5 and 4.8, respectively) in de novo DMRs
(Supplementary Figures S13A and S14). Plotting enrich-
ment rates in each case indicated that virtually all B-ALLs
are enriched for binding sites of the two TFs, with higher
rates in clusters III and IV (Supplementary Figure S13B).
The mean methylation at SUZ12-binding sites significantly
correlated with mean expression of polycomb target genes
(r = −0.276; P = 0.020), suggesting a substitutive and/or
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Figure 4. Enrichment of WGBS DMRs according to specific TFs, histone marks or motifs. (A and B) Positional enrichment of de novo DMRs and de-
DMRs of HD-ALL against 148 ENCODE TF-binding sites. Two transcription factors, SUZ12 and CTBP2, are highly enriched around de novo DMRs
while no specific TFs are enriched around de-DMRs. (C) Enrichment of DMRs of HD-ALL according to H3K4me3 (active) and H3K27me3 (repressive)
histone marks of H1 embryonic stem cell (ESC) shows remarkable enrichment of de novo DMRs in bivalent domain characterized by co-occupancy of
both histone marks (parallel analysis for ETV6-ALL is presented in Supplementary Figure S5A–C). (D) Positional analysis for histone and TF sites in ESC
shows enrichment of H3K4me3 at the center of CTBP2-binding site and dual peak of H3K27me3 around the ±1 kb region from the center, suggesting
CTBP2 constitute H3K4me3 part of the bivalent domain. (E) Methylation changes in an exemplary gene,ALX4. In human ESC (H1-hESC), the promoter
is poised bivalently with H3K4me3 (active) and H3K27me3 (repressive) histones marks. At differentiation, the gene is activated by H3K4me3 in normal
skeletal muscle (HSMM) and suppressed by H3K27me3 in normal lung fibroblasts (NHLF). In ALLs, promoters are mostly methylated (red bars) while
gene body is demethylated (blue bars). De novo DMRs frequently coincide with the bivalent regions, CGIs and SUZ12- and CTBP2-binding sites. Note
that H3K4me3 marks mostly peak around the CTBP2 sites. (F) Novel and known motifs significantly enriched around DMRs. Regions around de novo
DMRs are enriched for REST/NRSF, PU.1 and GATAmotifs and others, while those around de-DMRs are so for proto-oncogenes, ERG andMYC and
a developmental gene, EBF.
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Figure 5. Methylation profiles of 227 B-ALL cases analyzed by Illumina 450k array. (A) A hierarchical clustering analysis using 500 most variable CpGs
classifies the tumors into four distinct clusters. Some clusters are dominated by specific cytogenetic groups; cluster I by hyperdiploid, cluster II by others,
cluster III by ETV6/RUNX1, and cluster IV by hyperdiploid/others. (B) Local regression of the methylation differences illustrates that each methylation
cluster has different degrees of CGI methylation in each cytogenetics group. (C) Among the four methylation clusters, many DMRs are shared while some
DMRs were cluster-specific. (D) Mean methylation at SUZ12-binding sites significantly correlates with mean expression of polycomb target genes (9) (r=
−0.276; P = 0.020), suggesting a role of de novo methylation at polycomb sites for repressing their target genes.
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additive role of de novo methylation at polycomb sites for
repressing their target genes (Figure 5D).
Expression profiles in relation with methylation
For a randomly selected 81B-ALLs, we analyzed expression
profiles by microarray and paired them with DNA methy-
lation profiles. A negative correlation of CGIs around pro-
moters and a slight positive correlation of backbones in
main bodies were observed (Supplementary Figure S15A).
We have listed differentially expressed genes (DEGs) best
discriminating B-ALLs from pre-B cells including ELL2,
DDIT4, DRAM1, NR4A2, GAFA1 and some globin genes
(Supplementary Figure S16A). We also identified genes
specific to ETV6/RUNX1 (CLIC5, ACVR1C, IGF2BP1,
DSC2 and PCLO) and hyperdiploid (ZC3H12C, SH3BP5,
ZNF507, IL1B and PDGFA) groups (Supplementary Fig-
ure S16B and C). In hyperdiploid cases, the average ex-
pression levels did not differ between genes in disomy and
trisomy chromosomes, suggesting that copy number gain
contributes little to gene expression (Supplementary Figure
S15B).
We further performed pathway enrichment analysis us-
ing DEGs in comparison with pre-B-I and pre-B-II cells,
where most B-ALLs originate. Many pathways related to
hematopoietic cell development, cell cycle control and mis-
match repair were shown to be significantly dysregulated,
with more significant enrichment of methylation cluster III
for B-cell development and clusters II and IV for cell cy-
cle and mismatch repair. Glucocorticoid receptor signaling
wasmore significantly dysregulated in clusters I and II (Fig-
ure 6A).
Using the Ingenuity database, the activation z-scores of
numerous upstream regulators were calculated based on the
expression patterns of their downstream target genes. Chro-
matin modifiers including NUPR1, SMARCB1 and EP400
and cell cycle controllers including CCND1 and TBX2were
shown to be significantly dysregulated in addition to the
well-studied molecules, MYC, RB1, CDKN2A and TP53
(Figure 6B). NUPR1 was the most significantly activated
molecule with estimated actions to its target molecules to be
increased, and the activation score was less high in methyla-
tion cluster III (Supplementary Figure S17). Certain onco-
genic transcription networks related to tumor suppression
likeCDKN2A,RB1 andTP53 showed positive z-scores and
proto-oncogenes like MYC and TBX2 showed negative z
scores. Those activities did not always correlate with the
expression levels of the molecule itself, reflecting the com-
plexity between gene expression and function from various
interactions and feedback regulations (Supplementary Fig-
ure S18). Since these molecules dynamically change dur-
ing normal development, we further performed compar-
isons against each developmental stage of B-cell. Despite
the relatively higher activities of the tumor suppressors in B-
ALLs compared with normal pre-B cells, the leukemia cells
still possessed much lower activities than mature peripheral
B-cells. The inverse situation was the case for the proto-
oncogenes (Supplementary Figure S19). Many cytokines
including interferons, interleukins, and tumor necrosis fac-
tors and toll-like receptors were also significantly dysregu-
lated, especially in cluster I. To our interest, a conventional
drug for B-ALL, doxorubicin, and other trial drugs for B-
ALLs, including PD98059, SB203580, SP600125 and CpG
oligonucleotide, ranked among the most significant chem-
icals. This indicates that a substantial proportion of genes
and pathways pathobiologically dysregulated in cancers are
also downstream effectors of such drugs, and so adminis-
tration of these drugs may revert some dysregulated genes.
Although evidence is not sufficient at this time, the differ-
ent z-scores according to methylation clusters might indi-
cate that response to such drugs can be different according
to methylation clusters. This may be further investigated in
well controlled studies in the future.
DISCUSSION
Our analyses suggest that epigenetic modulations in B-
ALLs operate in two separate manners; small functional
compartments includingCGIs, promoters, TF-binding sites
and DNase HS are preferentially de novo methylated, and
large inter-compartmental backbones tend to be demethy-
lated in a subset of leukemias. We found the former modi-
fication is in large part related with the bivalent signatures
of ESCs that repress lineage-specific genes as well as those
repressive signatures of differentiated somatic cells that pre-
vent differentiation to other lineages. Since bivalent histone
mark sites in ESCs are known to largely overlap with poly-
comb binding sites and also with many CGIs, the de novo
methylation of these three sites have some commonality.
Interestingly, CGIs in leukemias were de novo methylated
throughout promoters and bodies in contrast to the nor-
mal physiologic state in which CGIs in gene bodies aremore
demethylated in down-regulated genes (16,17). This may
point toward a crude but still potent means of gene silenc-
ing in leukemogenesis.
We found an enrichment of CTBP2 sites in regions that
are hypermethylated in B-ALL. This suggests that CTBP2
may recruit factors that drive the observed hypermethyla-
tion. CTBP2 along with CTBP1 also function as transcrip-
tional corepressors by recruitment of histone deacetylases
or by their intrinsic enzymatic activities (20), and in cancer
cells, antagonize apoptosis by repressing tumor suppressor
genes (21). Interestingly, CTBPs serve as receptors for onco-
genic viruses such as Epstein-Barr virus and adenoviruses
(22). REST/NRSF, another TF remarkably enriched inmo-
tif scanning, was also recently identified as a polycomb re-
cruiter (23).
The global demethylation of backbones was observed
only in a subset of patients (clusters I and IV) and was even
subtle compared to the PMDs observed in other solid can-
cers and cultured cell-lines (11,24,25). Nonetheless, it is in-
triguing that the demethylation in B-ALLs occurs prefer-
entially in LADs where PMDs in other cancers largely co-
incide. LADs are large contiguous regions contacting nu-
clear periphery, characterized by transcriptionally repres-
sive environment from the unique epigenetic nature (14).
LADs also largely overlap with the large organized chro-
matin K9 modifications (LOCKs) (26). The majority of
LADs were shown to be constitutively conserved in vari-
ous tissues (15). In cancers, there is growing evidence that
DNA methylation becomes ‘destabilized’ through the hy-
pomethylated blocks or PMDs, giving rise to unregulated
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Figure 6. Pathway and upstream regulators dysregulated in different clusters. (A) Pathway enrichment analysis for differentially expressed genes (DEGs)
compared to pre-B-I and pre-B-II cells were done using the Ingenuity database. Values in boxes indicate -log(FDR-correctedP). B-cell development pathway
is more enriched for methylation cluster III, cell cycle and mismatch repair for clusters II and IV, and glucocorticoid receptor signaling for clusters I and II.
(B) Upstream regulators significantly dysregulated. Values in boxes display activation z scores calculated from the expression patterns of their downstream
target genes. Chromatin modifiers including NUPR1, SMARCB1 and EP400 and cell cycle controllers including CCND1 and TBX2 are significantly
dysregulated as well as MYC, RB1, CDKN2A and TP53. Among chemicals, doxorubicin and other investigative drugs for B-ALLs ranked at the top, with
different degrees according to methylation clusters.
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genome plasticity. The fact that LADs, LOCKs and PMDs
significantly overlap suggests that these domains may be re-
lated mechanistically (11,24,27). From an experiment treat-
ing B-ALL cell-lines with 5-aza-2′-deoxycytidine, we ob-
served demethylation does not lead to restoration of sup-
pressed genes in all cell lines, but can lead to preferential
restoration of polycomb identified genes when compared
to non-polycomb genes. This result is consistent with the
polycomb DNA methylation signature found in primary
leukemias.
Due to the limited availability of public data, functional
regions identified in various cell types were used for the en-
richment analysis and thus concerns about cell type-specific
bias may exist. Although these should be resolved in fur-
ther analyses using exact controls, our observation may still
provide relevant information since many regions like LADs
are shared across different cell types.Moreover, we retrieved
regions merged from all available tracks from the UCSC
genome database, as exemplified by DNase HS concate-
nated from a number of cell types, which may relieve biases
to some extent. Some regionsmay have specific implications
only in specific cell types, e.g. polycomb proteins like SUZ12
are hallmarks of ESCs, and seeing if the tumor cells ectopi-
cally gain signatures of other cell types may be sometimes
pertinent.
Through rigorous screening for upstream regulators us-
ing expression data, we identified candidate key molecules
and drugs thatmay have some therapeutic implications. The
most significant was NUPR1, a chromatin-binding protein
upregulated in response to cellular stress. NUPR1 has been
shown to play complicated roles as both inducer and sup-
pressor in cell and tumor growth and is also associated with
resistance to chemotherapeutic agents including doxoru-
bicin (28). NUPR1 was less activated in methylation cluster
III, the ETV6/RUNX1-dominant cluster. It is interesting
that B-ALLs with ETV6/RUNX1 actually showed superior
in vitro drug sensitivity to doxorubicin (29). SMARCB1 is
a core component of the BAF (hSWI/SNF) complex that
relieves repressive chromatic structures, allowing the tran-
scriptional machinery to access its targets effectively. De-
creased expression of SMARCB1 is reported to be related
with increased steroid resistance in B-ALLs (30). CCND1
or cyclin D1 is a protein involved in cell cycle progres-
sion from G1 to S phases. This molecule was also sug-
gested as a therapeutic target of farnesyltransferase in-
hibitors in B-ALL (31). Sincemany regulators and chemical
drugs showed different degrees of dysregulation according
tomethylation clusters, onemay suggest tailoring drug ther-
apies to suchDNAmethylation subtypes. Such an approach
will require further research and validation.
Collectively, we investigated DNA methylation profile
of B-ALLs at a base pair resolution with further valida-
tion by DNA methylation arrays. The observations here
suggest that B-ALLs inherit epigenetic patterns from their
cells of origin but also aberrantly have tumorigenic and
embryo-like signatures. Our data provide insight on epige-
netic switching in cancer as well as on the epigenetic hetero-
geneity of pediatric B-ALL.
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